Evidence map›Paper›PMID 33274559›Full record

ArticleOral diseases2022

Osteonecrosis of the jaw risk factors in bisphosphonate-treated patients with metastatic cancer.

Catherine Van Poznak, Evan L Reynolds, Cherry L Estilo, Mimi Hu, Bryan Paul Schneider, Daniel L Hertz, Christina Gersch, Jacklyn Thibert, Dafydd Thomas, Mousumi Banerjee and 2 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oral diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Interactive Associations betweenPharmaceuticals (Basel, Switzerland) · 2023
    Article
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Catherine Van PoznakDivision of Hematology Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
Evan L ReynoldsSchool of Public Health, University of Michigan, Ann Arbor, MI, USA.
Cherry L EstiloDental Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Mimi HuDepartment of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Bryan Paul SchneiderDivisions of Hematology/Oncology and Clinical Pharmacology, Department of Medicine with a Secondary Appointment in the Department of Medical and Molecular Genetics, Indiana University, Bloomington, IN, USA.
Daniel L HertzDepartment of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, MI, USA.ORCID https://orcid.org/0000-0003-0501-1035
Christina GerschDivision of Hematology Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
Jacklyn ThibertDepartment of Surgery, University of Michigan, Ann Arbor, MI, USA.
Dafydd ThomasDepartment of Pathology, University of Michigan, Ann Arbor, MI, USA.
Mousumi BanerjeeSchool of Public Health, University of Michigan, Ann Arbor, MI, USA.
James M RaeDivision of Hematology Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
Daniel F HayesDivision of Hematology Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
University of Michigan · USIndiana University Bloomington · USMemorial Sloan Kettering Cancer Center · USThe University of Texas MD Anderson Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
MICHIGAN INSTITUTE FOR CLINICAL AND HEALTH RESEARCH (MICHR) (UL1): (BPCA)UL1RR024986 · NCRR · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SHANLEY, THOMAS P. · 2007 to 2011
$51.2M
Genetic Risk of Osteonecrosis of the Jaw (ONJ) in Patients with Metastatic CancerK23DE020197 · NIDCR · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI VAN POZNAK, CATHERINE H · 2009 to 2013
$670k
Breast Cancer Research Foundation N003173Michigan Institute for Clinical and Health Research UL1RR024986NCI NIH HHS P30 CA008748NCRR NIH HHS UL1 RR024986NIDCR NIH HHS K23 DE020197NIDCR NIH HHS K23DE020197
6 · The paper itself

Abstract

backgroundA case-control study was performed to define clinical and genetic risk factors associated with osteonecrosis of the jaw in patients with metastatic cancer treated with bisphosphonates.

methodsClinical data and tissues were collected from patients treated with bisphosphonates for metastatic bone disease who were diagnosed with osteonecrosis of the jaw (cases) and matched controls. Clinical data included patient, behavioral, disease, and treatment information. Genetic polymorphisms in CYP2C8 (rs1934951) and other candidate genes were genotyped. Odds ratios from conditional logistic regression models were examined to identify clinical and genetic characteristics associated with case or control status.

resultsThe study population consisted of 76 cases and 126 controls. In the final multivariable clinical model, patients with osteonecrosis of the jaw were less likely to have received pamidronate than zoledronic acid (odds ratio = 0.18, 95% Confidence interval: 0.03-0.97, p = .047) and more likely to have been exposed to bevacizumab (OR = 5.15, 95% CI: 1.67-15.95, p = .005). The exploratory genetic analyses suggested a protective effect for VEGFC rs2333496 and risk effects for VEGFC rs7664413 and PPARG rs1152003.

conclusionsWe observed patients with ONJ were more likely to have been exposed to bevacizumab and zoledronic and identified potential genetic predictors that require validation prior to clinical translation.

Indexed as

Bone Density Conservation AgentsNeoplasmsOsteonecrosisCase-Control StudiesDiphosphonatesHumansRisk FactorsBone Density Conservation AgentsDiphosphonatesbevacizumabbisphosphonateoncologypharmacogeneticsrisk factorsVEGFCzoledronic acid

Identifiers

PMID33274559
PMCPMC8284838
OpenAlexW3110629205

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.